GMED - Globus Medical Inc Stock Price, Fair Value and News

61.74USD+10.38 (+20.21%)Market Closed

Market Summary

USD61.74+10.38

Market Closed

20.21%

GMED Alerts

Big jump in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

GMED Stock Price

View Fullscreen

GMED RSI Chart

GMED Valuation

Market Cap

8.3B

Price/Earnings (Trailing)

129.88

Price/Sales (Trailing)

4.39

EV/EBITDA

29.25

Price/Free Cashflow

54.96

GMED Price/Sales (Trailing)

GMED Profitability

EBT Margin

4.93%

Return on Equity

1.64%

Return on Assets

1.3%

Free Cashflow Yield

1.82%

GMED Fundamentals

GMED Revenue

Revenue (TTM)

1.9B

Rev. Growth (Yr)

119.26%

Rev. Growth (Qtr)

-1.6%

GMED Earnings

Earnings (TTM)

64.2M

Earnings Growth (Yr)

-113.1%

Earnings Growth (Qtr)

-158.09%

Breaking Down GMED Revenue

Last 7 days

22.4%

Last 30 days

16.1%

Last 90 days

17.6%

Trailing 12 Months

9.0%

How does GMED drawdown profile look like?

GMED Financial Health

Current Ratio

2.33

Debt/Equity

0.11

Debt/Cashflow

0.58

GMED Investor Care

Shares Dilution (1Y)

34.61%

Diluted EPS (TTM)

0.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.9B	0	0	0
2023	1.1B	1.1B	1.2B	1.6B
2022	961.3M	973.9M	998.4M	1.0B
2021	825.8M	927.9M	941.5M	958.1M
2020	793.0M	747.4M	767.3M	789.0M
2019	721.5M	742.7M	769.6M	785.4M
2018	654.6M	675.6M	693.1M	713.0M
2017	580.5M	595.4M	611.5M	636.0M
2016	552.4M	556.3M	555.0M	564.0M
2015	491.8M	511.8M	531.0M	544.8M
2014	443.7M	450.2M	460.8M	474.4M
2013	396.3M	407.3M	419.8M	434.5M
2012	347.9M	363.0M	373.5M	386.0M
2011	299.0M	309.8M	320.7M	331.5M
2010	0	0	0	288.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Globus Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	norwalk leslie v	sold	-550,574	51.99	-10,590	-
Mar 01, 2024	huller kelly	sold	-405,730	54.0973	-7,500	svp, gc, corporate secretary
Mar 01, 2024	huller kelly	acquired	186,750	24.9	7,500	svp, gc, corporate secretary
Jan 18, 2024	davidar david d	gifted	-	-	-8,000	-
Sep 01, 2023	wolterman dan	acquired	-	-	24,025	-
Sep 01, 2023	deford john a	acquired	-	-	15,578	-
Sep 01, 2023	norwalk leslie v	acquired	-	-	28,009	-
May 15, 2023	lemaitre dan	acquired	1,104,780	25.4265	43,450	-
May 15, 2023	lemaitre dan	sold	-2,475,980	56.9845	-43,450	-
Feb 09, 2023	lemaitre dan	acquired	132,922	23.95	5,550	-

Which funds bought or sold GMED recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Inspire Investing, LLC	reduced	-7.29	-25,493	356,223	0.04%
May 07, 2024	MONTAG A & ASSOCIATES INC	new	-	1,153	1,153	-%
May 07, 2024	SEI INVESTMENTS CO	reduced	-31.94	-1,964,490	4,271,980	0.01%
May 07, 2024	Swiss National Bank	reduced	-1.51	-106,793	12,218,000	0.01%
May 07, 2024	Paradice Investment Management LLC	reduced	-15.85	-6,211,730	34,386,500	5.96%
May 07, 2024	Washington Trust Advisors, Inc.	reduced	-18.17	-994,817	4,647,100	0.43%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-69.83	-5,815,730	2,535,780	-%
May 07, 2024	SYNTAX RESEARCH, INC.	unchanged	-	350	53,640	0.04%
May 07, 2024	RIVER GLOBAL INVESTORS LLP	added	47.45	701,119	2,149,460	0.54%
May 07, 2024	Mitsubishi UFJ Asset Management (UK) Ltd.	added	20.98	166,000	928,000	0.47%

Are Funds Buying or Selling GMED?

Are funds buying GMED calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GMED

No. of Funds

Unveiling Globus Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	paul david c	15.76%	21,304,758	SC 13G/A
Feb 13, 2024	janus henderson group plc	5.7%	7,908,828	SC 13G/A
Feb 13, 2024	vanguard group inc	9.54%	11,277,722	SC 13G/A
Feb 13, 2024	kayne anderson rudnick investment management llc	0.00%	0	SC 13G/A
Jan 24, 2024	blackrock inc.	9.4%	10,841,823	SC 13G/A
Sep 11, 2023	vanguard group inc	14.46%	11,283,774	SC 13G/A
Sep 07, 2023	blackrock inc.	12.1%	9,456,012	SC 13G/A
Feb 14, 2023	paul david c	21.57%	21,389,400	SC 13G/A
Feb 14, 2023	kayne anderson rudnick investment management llc	7.99%	6,184,472	SC 13G
Feb 10, 2023	janus henderson group plc	5.6%	5,633,954	SC 13G/A

Recent SEC filings of Globus Medical Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	144	Notice of Insider Sale Intent
May 08, 2024	144	Notice of Insider Sale Intent
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	4	Insider Trading
Mar 01, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Globus Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

Globus Medical Inc News

Latest updates

Globus Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.6%	607	617	384	292	277	274	254	264	231	250	230	251	227	233	216	149	191	212	196	195	183
Gross Profit	4.0%	365	351	248	215	206	204	189	195	171	188	171	187	172	173	159	98.00	142	163	151	151	141
Operating Expenses	4.8%	357	341	248	149	149	150	129	127	125	170	118	141	118	114	109	124	113	113	109	108	104
S&GA Expenses	1.6%	249	245	156	120	122	118	107	107	101	107	96.00	107	98.00	92.00	89.00	80.00	94.00	92.00	88.00	88.00	86.00
R&D Expenses	9.6%	57.00	52.00	29.00	21.00	21.00	20.00	19.00	17.00	17.00	51.00	16.00	16.00	15.00	15.00	14.00	39.00	15.00	15.00	15.00	16.00	14.00
EBITDA Margin	-28.1%	0.15*	0.21*	0.26*	0.32*	0.32*	0.32*	0.28*	0.28*	0.26*	0.27*	0.32*	0.33*	-	-	-	-	-	-	-	-	-
Interest Expenses	26.6%	-1.89	-2.58	8.00	8.00	6.00	5.00	4.00	2.00	3.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00
Income Taxes	-114.5%	-1.44	10.00	2.00	17.00	14.00	12.00	14.00	16.00	11.00	5.00	7.00	7.00	12.00	9.00	9.00	-1.10	7.00	9.00	8.00	9.00	8.00
Earnings Before Taxes	-134.2%	-8.56	25.00	3.00	75.00	63.00	62.00	61.00	71.00	49.00	20.00	54.00	49.00	57.00	62.00	53.00	-21.94	32.00	54.00	47.00	47.00	42.00
EBT Margin	-53.2%	0.05*	0.11*	0.17*	0.24*	0.24*	0.24*	0.20*	0.20*	0.18*	0.19*	0.24*	0.24*	-	-	-	-	-	-	-	-	-
Net Income	-158.1%	-7.12	12.00	1.00	58.00	54.00	58.00	47.00	46.00	28.00	11.00	46.00	42.00	40.00	55.00	45.00	-13.27	23.00	45.00	37.00	42.00	35.00
Net Income Margin	-57.8%	0.03*	0.08*	0.14*	0.20*	0.19*	0.18*	0.13*	0.13*	0.13*	0.14*	0.19*	0.20*	-	-	-	-	-	-	-	-	-
Free Cashflow	-70.9%	24.00	82.00	29.00	17.00	37.00	46.00	21.00	13.00	25.00	59.00	59.00	51.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.8%	4,944	5,086	5,356	2,212	2,150	2,076	1,977	1,915	1,999	1,957	1,911	1,830	1,738	1,679	1,542	1,466	1,479	1,532	1,452	1,391	1,336
Current Assets	-4.5%	1,829	1,915	1,917	1,210	1,070	983	920	891	917	865	981	892	814	822	812	697	642	687	637	584	618
Cash Equivalents	-24.2%	354	467	280	306	218	150	134	151	230	193	362	269	185	239	251	166	167	196	166	118	130
Inventory	-3.8%	816	848	905	336	321	299	282	266	254	237	234	231	232	229	232	224	208	196	187	173	143
Net PPE	-1.4%	579	587	607	248	245	244	236	239	228	221	216	211	216	217	215	212	213	200	197	194	184
Goodwill	1.2%	1,451	1,435	924	199	199	197	182	5.00	179	180	11.00	156	155	157	26.00	129	129	129	129	130	124
Liabilities	-6.1%	1,021	1,088	1,169	227	235	230	212	216	213	216	192	191	175	173	125	129	116	130	113	103	99.00
Current Liabilities	100.4%	786	392	429	155	168	159	145	146	141	140	123	130	124	121	100	106	98.00	111	95.00	84.00	79.00
Long Term Debt	-100.0%	-	417	410	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	417	410	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-1.9%	3,922	3,998	4,187	1,985	1,915	1,846	1,764	1,699	1,785	1,741	1,718	1,639	1,563	1,506	1,417	1,337	1,363	1,402	1,339	1,288	1,237
Retained Earnings	-8.0%	1,047	1,137	1,348	1,347	1,289	1,240	1,190	1,142	1,232	1,194	1,179	1,132	1,090	1,045	992	948	1,000	1,048	1,002	964	926
Additional Paid-In Capital	0.5%	2,886	2,871	2,858	657	645	631	606	582	570	554	542	509	474	457	423	388	370	357	339	325	317
Accumulated Depreciation	5.0%	447	426	388	364	354	343	333	322	314	306	301	294	282	276	267	258	250	244	238	231	224
Shares Outstanding	19.7%	135	113	105	100	100	100	101	101	102	101	100	100	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,600	-	-	-	4,300	-	-	-	5,900	-	-	-	3,500	-	3,300	-	3,300	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-50.0%	52,387	104,674	50,484	35,028	53,313	63,975	32,920	36,883	44,690	76,253	77,262	59,189	63,570	80,184	53,248	23,068	42,293	54,309	55,866	22,597	39,203
Share Based Compensation	38.7%	17,260	12,445	22,755	8,589	8,953	8,507	8,314	7,837	8,152	7,805	7,451	7,632	7,698	5,935	7,020	7,311	6,807	6,438	6,898	6,301	6,448
Cashflow From Investing	-114.5%	-46,584	320,615	-80,861	52,222	10,992	-60,484	-63,110	27,126	-13,894	-243,797	-6,885	-143	-125,114	-119,092	7,661	-3,299	-2,592	-36,035	-13,668	-36,739	-53,839
Cashflow From Financing	51.2%	-115,721	-237,270	1,425	1,084	2,940	13,591	13,162	-142,762	6,047	-1,023	22,678	24,928	7,564	27,212	23,683	-20,891	-68,667	11,185	6,619	1,730	4,905
Buy Backs	-	83,315	-	-	-	-	-	-	144,493	-	-	-	-	-	-	-	30,805	73,864	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GMED Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME [Abstract]
Net sales	$ 606,666	$ 276,688
Cost of sales	241,487	70,825
Gross profit	365,179	205,863
Operating expenses:
Research and development	57,268	21,082
Selling, general and administrative	248,710	122,416
Provision for litigation, net	(31)
Amortization of intangibles	29,676	4,601
Acquisition-related costs	2,418	1,361
Restructuring Costs	19,141
Total operating expenses	357,182	149,460
Operating income/(loss)	7,997	56,403
Other income/(expense), net
Interest income/(expense), net	(1,894)	6,497
Foreign currency transaction gain/(loss)	(15,371)	212
Other income/(expense)	710	77
Total other income/(expense), net	(16,555)	6,786
Income/(loss) before income taxes	(8,558)	63,189
Income tax provision/(benefit)	(1,441)	14,060
Net income/(loss)	(7,117)	49,129
Other comprehensive income/(loss), net of tax:
Unrealized gain/(loss) on marketable securities	379	4,298
Foreign currency translation gain/(loss)	(1,232)	910
Total other comprehensive income/(loss), net of tax	(853)	5,208
Comprehensive income/(loss)	$ (7,970)	$ 54,337
Earnings per share:
Basic	$ (0.05)	$ 0.49
Diluted	$ (0.05)	$ 0.48
Weighted average shares outstanding:
Basic	135,358	100,279
Diluted	135,358	102,196

GMED Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 354,062	$ 467,292
Short-term marketable securities	80,408	50,497
Accounts receivable, net of allowances of $11,527 and $8,934, respectively	534,333	503,235
Inventories	816,196	848,135
Prepaid expenses and other current assets	43,209	44,580
Income taxes receivable	366	1,635
Total current assets	1,828,574	1,915,374
Property and equipment, net of accumulated depreciation of $447,122 and $425,695, respectively	578,887	586,932
Operating lease right of use assets	56,347	59,931
Long-term marketable securities	51,256	75,428
Intangible assets, net	888,208	924,603
Goodwill	1,451,106	1,434,540
Other assets	78,216	78,590
Deferred income taxes	11,018	10,685
Total assets	4,943,612	5,086,083
Current liabilities:
Accounts payable	50,487	56,671
Accrued expenses	210,011	240,460
Operating lease liabilities	11,749	11,967
Income taxes payable	43,058	3,845
Senior convertible notes	424,044
Business acquisition liabilities	29,649	61,035
Deferred revenue	17,077	18,369
Payable to broker	249
Total current liabilities	786,324	392,347
Business acquisition liabilities, net of current portion	81,661	78,323
Operating lease liabilities	89,809	91,037
Senior convertible notes		417,400
Deferred income taxes and other tax liabilities	39,952	84,421
Other liabilities	23,505	24,596
Total liabilities	1,021,251	1,088,124
Commitments and contingencies (Note 17)
Equity:
Additional paid-in capital	2,886,436	2,870,749
Accumulated other comprehensive income/(loss)	(11,045)	(10,192)
Retained earnings	1,046,835	1,137,266
Total equity	3,922,361	3,997,959
Total liabilities and equity	4,943,612	5,086,083
Common Class A [Member]
Equity:
Common stock	113	114
Common Class B [Member]
Equity:
Common stock	$ 22	$ 22

About Globus Medical Inc

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

CEO	Mr. Daniel T. Scavilla
WEBSITE	globusmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2600

Globus Medical Inc Frequently Asked Questions

What is the ticker symbol for Globus Medical Inc? What does GMED stand for in stocks?

GMED is the stock ticker symbol of Globus Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Globus Medical Inc (GMED)?

As of Wed May 08 2024, market cap of Globus Medical Inc is 8.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GMED stock?

You can check GMED's fair value in chart for subscribers.

What is the fair value of GMED stock?

You can check GMED's fair value in chart for subscribers. The fair value of Globus Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Globus Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GMED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Globus Medical Inc a good stock to buy?

The fair value guage provides a quick view whether GMED is over valued or under valued. Whether Globus Medical Inc is cheap or expensive depends on the assumptions which impact Globus Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GMED.

What is Globus Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, GMED's PE ratio (Price to Earnings) is 129.88 and Price to Sales (PS) ratio is 4.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GMED PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Globus Medical Inc's stock?

In the past 10 years, Globus Medical Inc has provided 0.101 (multiply by 100 for percentage) rate of return.